Keywords: astrazeneca, net, profit, falls, restructing, charges, medimmune
AstraZeneca's net profit falls 12% on restructing charges from MedImmune buy, lower Nexium sales
Article | 11 February 2008
AstraZeneca's fourth-quarter 2007 net profit fell 12% year-on-year to a disappointing $1.28 billion after $362.0 million in restructing costs related to last year's $15.6 billion ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
